Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites
Key facts
- Who runs it
- Institute of Liver and Biliary Sciences, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 61 people enrolled
- Started
- 22 Dec 2023
- Ended
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Midodrine
- albumin
- Standard Medical Treatment
- Record updated
- 10 March 2026
Who can take part
- Age
- 12 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Children (≤ 18 years)
- Cirrhosis based on histological/ radiological + endoscopic evidence
- Clinical ascites (≥ grade 2 ascites)
- Informed consent from parents (Assent > 12 years)
Who cannot take part
- Presence of Portal vein thrombosis
- Hepatorenal Syndrome
- Congestive Heart failure
- Respiratory failure(PF ratio <200)
- Arterial hypertension (Mean Arterial Pressure ≥ 95th centile for age)
- Septic shock
- Presence of Hepatocellular Carcinoma
- Transjugular intrahepatic Porto Systemic Shunt
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Children with decompensated cirrhosis are more prone to develop various complications. The pathogenesis of cirrhotic complications (ascites, hyponatremia, acute kidney injury) includes release of vasodilatory molecules like nitric oxide, damage associated molecular pathogens (DAMPs) and pattern associated molecular pathogens (PAMPs) secondary to bacterial translocation, which causes splanchnic bed vasodilation resulting in activation of renin-angiotensin and aldosterone axis (RAAS) causing sodium and water retention and renal vasoconstriction.
Read full original descriptionShow less
The development of complications in these children may result in death or may preclude them from reaching upto liver transplantation.
Midodrine is an α1 adrenergic receptor agonist, which increases vascular tone causing rise in the blood pressure, thereby improving renal perfusion and causes RAAS deactivation. The effects of midodrine is documented in reduction of refractory ascites, hepatorenal syndrome and hyponatremia.
Albumin is a protien that works by both increasing the colloidal oncotic pressure and improving systemic circulation as well as by effecting the body with anti-inflammatory and antioxidant properties.
We have already demonstrated the safety and efficacy of midodrine as well as albumin in cirrhotic children. However, none of these drugs alone provided survival benefit to the patients. Hence, we have planned this study with the ojective to evaluate if combining these 2 drugs (midodrine and albumin) would further reduce the complications and improve the survival in decompensated cirrhotic children.
The 2 groups in the trial
- Midodrine+Albumin+SMTTreatment being tested
* Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is \< 3.5 gm/dl Plus * Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% . In addition, standard medical therapy will be administered to patients in both the arms.
Treatment: Midodrine, albumin, and Standard Medical Treatment
- Midodrine+SMTExisting treatment, for comparison
• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% In addition, standard medical therapy will be administered to patients in both the arms.
Treatment: Midodrine and Standard Medical Treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites - An Open Label Randomized Controlled Trial.
- Record updated
- 10 March 2026